Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-24Clinical Trial Update: Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy [Phase 4]
Phase 4 trial evaluating Active Vitamin D with reduced-dose prednisolone for Minimal Change Disease and Nephrotic Syndrome; the study has co…
-
FDA approval · 2025-01-23FDA Approved: SPIRONOLACTONE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved the original application for spironolactone (generic) from Rising Pharma Holdings, Inc., authorizing the marketing of a gen…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Amiloride in Nephrotic Syndrome [Phase 3]
A Phase 3 trial evaluating amiloride for nephrotic syndrome was terminated, and the results have been posted.
-
FDA approval · 2024-12-13FDA Approved: FUROSEMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for furosemide, enabling a generic version of the loop diuretic to be marketed.
-
FDA approval · 2024-11-06FDA Approved: METOLAZONE — Original Application (Micro Labs Limited)
The FDA approved the generic METOLAZONE from Micro Labs Limited under an Original Application. This metolazone product is a thiazide-like di…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
ClinicalTrials.gov update describes a study on genetic causes of focal segmental glomerulosclerosis, nephrotic syndrome, and related kidney …
-
CLINICAL_TRIALS research · 2024-10-02Clinical Trial Update: Cardiac Performance Evaluation in Children With Steroid Dependent vs Steroid Resistant Nephrotic Syndrome [NA]
A clinical trial is evaluating cardiac performance in children with nephrotic syndrome, comparing steroid-dependent and steroid-resistant ca…
-
FDA approval · 2024-10-01FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)
The FDA approved a supplemental application for furosemide from Phlow Corporation, authorizing an additional or revised approval for the diu…
-
FDA approval · 2024-09-19FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for hydrochlorothiazide from Teva Pharmaceuticals USA, Inc. The approval concerns regulatory changes…
-
CLINICAL_TRIALS research · 2024-08-21Clinical Trial Update: Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome [Phase 3]
A Phase 3 clinical trial is ongoing to evaluate the safety and efficacy of Telitacicept in pediatric patients with frequently relapsing or s…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
This document reports a clinical follow-up study evaluating rituximab for nephrotic syndrome in children, currently recruiting participants.
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Electroencephalographic Changes in Nonconvulsive Children With Chronic Renal Disease
This clinical trial update describes a study on electroencephalographic changes in nonconvulsive children with chronic kidney disease, with …
-
CLINICAL_TRIALS research · 2024-06-21Clinical Trial Update: The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children [Phase 4]
A Phase 4 clinical trial assessing the efficacy and safety of prednisone combined with Huaiqihuang granule for nephrotic syndrome, in childr…
-
CLINICAL_TRIALS research · 2024-06-05Clinical Trial Update: Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1
Clinical trial update investigating predictive determinants of nephrotic syndrome remission in patients with at-risk APOL1 polymorphisms, in…
-
FDA approval · 2024-04-30FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for hydrochlorothiazide filed by Accord Healthcare Inc. under ANDA 202556. The document does not…
-
CLINICAL_TRIALS research · 2024-04-29Clinical Trial Update: Steroid Diabetes in Patients With Kidney Disease
An ongoing clinical trial sponsored by Zhejiang Provincial People's Hospital is investigating steroid-related diabetes in patients with neph…
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome [Phase 2]
Phase 2 study of CCX140-B in subjects with primary FSGS and nephrotic syndrome was terminated. Results have been posted on 2024-02-06.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Prednisolone Trial in Children Younger Than 4 Years [Phase 3]
Phase 3 clinical trial update evaluating prednisolone in children under 4 with nephrotic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients [Phase 4]
A Phase 4 clinical trial evaluating how obesity affects cyclosporine trough levels in patients with nephrotic syndrome.
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy of combining an anti-CD20 antibody with an anti-CD38 antibody in childhood nephrotic syn…
-
FDA approval · 2023-10-10FDA Approved: SPIRONOLACTONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for spironolactone by Mylan Pharmaceuticals Inc., updating the approval for this generic diuretic. T…
-
CLINICAL_TRIALS research · 2023-09-07Clinical Trial Update: Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome [Phase 4]
A Phase 4 trial evaluating the clinical value of adding dapagliflozin in patients with nephrotic syndrome.
-
FDA approval · 2023-09-05FDA Approved: SPIRONOLACTONE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original ANDA for spironolactone from Amneal Pharmaceuticals NY LLC, enabling a generic version of the diuretic.
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome. [Phase 4]
Phase 4 trial investigating the effect of dapagliflozin in non-diabetic patients with nephrotic syndrome is ongoing; current status is unkno…
-
FDA approval · 2023-07-24FDA Approved: BUMETANIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' original ANDA for bumetanide, a loop diuretic used to treat edema and related conditions.